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Background: Due to global mercury pollution and the adverse health effects of prenatal exposure to
methylmercury (MeHg), an assessment of the economic benefits of prevented developmental neurotoxicity is
necessary for any cost-benefit analysis.
Methods: Distributions of hair-Hg concentrations among women of reproductive age were obtained from the
DEMOCOPHES project (1,875 subjects in 17 countries) and literature data (6,820 subjects from 8 countries). The
exposures were assumed to comply with log-normal distributions. Neurotoxicity effects were estimated from a
linear dose-response function with a slope of 0.465 Intelligence Quotient (IQ) point reduction per μg/g increase in
the maternal hair-Hg concentration during pregnancy, assuming no deficits below a hair-Hg limit of 0.58 μg/g
thought to be safe. A logarithmic IQ response was used in sensitivity analyses. The estimated IQ benefit cost was
based on lifetime income, adjusted for purchasing power parity.
Results: The hair-mercury concentrations were the highest in Southern Europe and lowest in Eastern Europe. The
results suggest that, within the EU, more than 1.8 million children are born every year with MeHg exposures above
the limit of 0.58 μg/g, and about 200,000 births exceed a higher limit of 2.5 μg/g proposed by the World Health
Organization (WHO). The total annual benefits of exposure prevention within the EU were estimated at more than
600,000 IQ points per year, corresponding to a total economic benefit between €8,000 million and €9,000 million
per year. About four-fold higher values were obtained when using the logarithmic response function, while
adjustment for productivity resulted in slightly lower total benefits. These calculations do not include the less
tangible advantages of protecting brain development against neurotoxicity or any other adverse effects.
Conclusions: These estimates document that efforts to combat mercury pollution and to reduce MeHg exposures
will have very substantial economic benefits in Europe, mainly in southern countries. Some data may not be
entirely representative, some countries were not covered, and anticipated changes in mercury pollution all suggest
a need for extended biomonitoring of human MeHg exposure.
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Methylmercury (MeHg) is a well-documented neurotoxicant,
and prenatal exposures are therefore of particular concern
[1,2]. The main sources of exposure are seafood and
freshwater fish [3]. Thus, MeHg exposures vary with dietary
habits, contamination levels, and species availability. While
the distribution of MeHg exposures has been studied in
substantial detail in the United States [4], only scattered
information is available on MeHg exposures in Europe.
Because the critical effect of MeHg exposure is develop-
mental brain toxicity, exposures among women of repro-
ductive age groups are of primary concern [5,6]. As has
previously been determined in regard to lead exposure [7],
developmental MeHg exposure is linked to a loss in
Intelligence Quotient (IQ), with associated lower school
performance and educational attainment, thereby leading
to long-term impacts on societal benefits of pollution
abatement [8]. These consequences may be expressed in
terms of economic impacts, as has been demonstrated in
United States [9,10]. However, few economic evaluations
have been performed in Europe [8,11,12], primarily because
of the lack of exposure data.
Based on harmonised protocols developed in COPHES
[13], the DEMOCOPHES project has just completed a
multi-country study of hair-mercury concentrations in
women of reproductive age groups in 17 European
countries. In conjunction with literature data, we now
utilise the exposure data to generate estimates of
economic impacts of MeHg exposures in Europe.
The economic assessment relies on several assumptions.
The hair-Hg concentrations is used as the main exposure
indicator in this study, and any blood-based measurements
also considered are expressed in terms of hair-mercury
using a conversion factor of 250 [14,15]. In regard to the
dose-response function (DRF), a linear model is usually
the default [14], although it may not necessarily pro-
vide the best statistical fit to the data [16]. We there-
fore used the linear slope as the primary DRF and then
conducted a sensitivity analysis using the log function,
where each doubling of exposure above the background
causes the same deficit of 1.5 IQ points [10].
With regard to background exposures and the possible
existence of a threshold, the U.S. EPA’s Reference Dose
(RfD) of 0.1 μg/kg body weight/day corresponds to a
hair-Hg concentration of about 1 μg/g hair [14]. Updated
calculations [17] resulted in an adjusted biological limit
about 50% below the recommended level, corresponding to
0.58 μg/g hair. The validity of this lower cut-off point below
the RfD is supported by recent studies of developmental
neurotoxicity at exposure levels close to the background
[18-21]. We assumed that, below the 0.58 μg/g cut-off
point, only negligible adverse effects would exist. As
additional reference point, we use a tolerable limit
proposed by the World Health Organization (WHO),which corresponds to a hair-Hg concentration of
approximately 2.5 μg/g [22]. This limit takes into account
the possible compensation of MeHg toxicity by beneficial
nutrients in seafood [22].
Methods
Exposure information
DEMOCOPHES is a cross-sectional survey of European
population exposure to environmental chemicals. The
human exposure biomarkers included the hair-mercury
concentration and was collected in 17 European
countries based on children aged 6–11 years and their
mothers. A common European protocol, developed by
the COPHES project, was followed in each country. The
main inclusion and exclusion criteria were (1) residence
in the study area for at least five years, and (2) not
having metabolic disturbances. The period of sampling
was September 2011 to February 2012. A total of 1,875
child-mother pairs were recruited from urban and rural
communities in the participating countries, while
excluding exposure hot-spots. Major efforts were carried
out to achieve high quality and comparability of data.
Standard operational procedures for total mercury
concentrations in hair were developed and validated by
the Laboratory of Environmental Toxicology in Spain, to
ensure comparable measurements, which included a strict
quality assurance programme, in which seventeen
European laboratories participated. Each DEMOCOPHES
partner contributed information to allow estimation of the
underlying distribution of exposures in the population,
where rural and urban results were merged. In addition,
each partner provided the frequencies of results above the
cut-off levels of 0.58 μg/g, 1.0 μg/g, and 2.5 μg/g. The
latter corresponds to WHO’s tolerable limit, which takes
into account likely toxicity compensation by beneficial
nutrients in seafood [22].
Additional information on MeHg exposures in Europe
was obtained to complement the DEMOCOPHES data.
Thus, information of similar quality was extracted from
published articles (Miklavčič, unpublished data), and
distribution information from comparable studies was
obtained from Belgium, Denmark, France, Norway,
Slovenia, and the United Kingdom. As explained
below, missing information was calculated assuming a
log-normal distribution of the exposures.
Exposure distributions
Using the number of births in 2008 and the observed hair-
Hg concentrations, we estimated the number of births
exceeding the three exposure limits for each country and
obtained the sum for all of the EU. For missing EU member
states, MeHg exposures were assumed to be the same as a
neighbouring country. The year 2008 was chosen as the
closest to the time during which the exposure data had
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calculations envisaged. Due to the existence of sampling
uncertainty, “smoothed” proportions exceeding the three
limits were calculated assuming log-normal distributions.
Because log-transformed concentrations would follow a
normal distribution, the parameters in the log-normal
distributions could be estimated by standard normal distri-
bution methods. Each data set included probabilities (prob)
for being below specific percentiles (perc). The parameters
in the logarithmic distributions were therefore obtained as
the intercept and slope when regressing log(perc) on Φ-1
(prob), where Φ is the cumulative distribution function of
the standard normal distribution. Using the total numbers
of births in 2008, numbers of births exceeding the three
cut-off limits in each country were calculated from
observed and smoothed distributions.
Calculation of IQ benefits
A linear dose-response function was applied as the default
model [14]. Thus, as a 1 μg/L increase of the cord-blood
mercury concentration is associated with an average
adverse impact on IQ of 0.093 times the standard deviation
(which is standardised to be 15), each increase in the ma-
ternal hair-mercury by 1 μg/g is associated with an average
loss of 0.465 IQ points [10]. This slope is based on a range
of neuropsychological tests and subtests administered in
the Faroe Islands study at age 7 years [23]. As some recent
studies [18-21] suggest MeHg-associated deficits close to
or below the cut-off level of 0.58 μg/g hair, the calculations
may represent an underestimate. In addition, the slope
may be steeper at low exposure levels. Thus, a log model
was used for sensitivity analyses. In this model, a doubling
in prenatal MeHg exposures is associated with a delay in
development of 1.5–2 months at age 7, which corresponds
to about 10% of the standard deviation, i.e. 1.5 IQ points
[1]. Again, we applied this slope for exposures above the
0.58 μg/g the cut-off point.
To estimate the benefits at exposures above the cut-off
point, we calculated the average hair-mercury concentration
in women exceeding 0.58 μg/g based on 1,000,000
simulations from the estimated log-normal distribution
(as described above). After deduction of the 0.58 μg/g and
multiplication by the slope factor, an average IQ benefit
was obtained. This amount was then multiplied by the
annual number of births exceeding the cut-off level. A simi-
lar calculation was made in the logarithmic dose-response
model except that here we calculated the average log-
transformed mercury concentration in women exceeding
0.58 μg/g, deducted log(0.58) and multiplied by the slope
factor of the logarithmic dose-response model (1.5/log(2)).
Annual benefits of exposure reduction
The major component of the social costs incurred by an
IQ reduction is loss of productivity and thus a lowerearning potential [9,24]. The economic consequence of
prenatal exposure to MeHg is valued as the lifetime
earning loss per person. We assumed singleton births
only, so that the number of women was equal to the
cohort size. We also assumed that IQ deficits present at
age 7 years or preschool ages are permanent [25]. The
estimated individual benefits are the avoided lifetime
costs using 2008 data (slightly lower benefits are
obtained if referring to more recent years, and benefits
are only minimally affected by subsequent membership
of the Euro zone). The benefit estimates originate from
the 2008 figure of €17,363 per IQ point as recently
calculated for France based on data from the United
States [24]. For the various European countries involved,
this value is adjusted for differences in purchasing
power. While simple currency exchange conversion and
Gross Domestic Product (GDP) per capita do not adjust
for price differences, Purchasing Power Parity (PPP) con-
version rates allow for comparison based on a common set
of average international prices [26,27]. We also carried out
the calculations after adjustment for productivity as the
ratio of PPP-adjusted real GDP/capita in each country in
relation to the US as a reference. The estimated value of an
IQ point then takes into account the impact of labour costs
and productivity (Additional file 1).
Results
Table 1 and Additional file 2 show summary information
on MeHg exposures in the European countries covered
by DEMOCOPHES or other exposure studies. There is a
clear trend from north and east to southern countries, most
likely due to differences in dietary habits and availability of
large fish species from the Mediterranean (the sources of
exposure were not considered in the present study). In
Table 1, exposures in Austria were assumed to be similar to
those in Germany, as suggested by available data [28].
Exposure information from the Flemish part of Belgium
[29,30] do not differ much from the national data obtained
in DEMOCOPHES, which were therefore used for the
calculations. The Flemish data were used to represent
exposures in The Netherlands. In the absence of exposure
data from Estonia, Finland, Latvia, and Lithuania, the
DEMOCOPHES exposure information from Sweden was
applied. National data from France are available [31] and
have been used in recent economic calculations [8]. Data
for Croatia and Greece were obtained from a recent birth
cohort study [32]. Two exposure studies had been carried
out in Italy, one in the northeast [32] and one in Naples
[33], and a joint distribution was therefore used to obtain
national exposure distributions that would also apply to
Malta. Thus, a log-normal distribution was first fitted to
each Italian data subset, and then the parameters of a joint
log-normal distribution were determined as the mean of
the parameters for the two distributions. Recent results
Table 1 Annual numbers of births and numbers exceeding three cut-off limits, as indicated by hair-mercury analyses
(in μg/g) in population samples in European countries
Countrya Annual number
of births (2008)
Number of
samplesb
Above 0.58 μg/g Above 1.0 μg/g Above 2.5 μg/g
Proportion in
sample (%)
Estimated
number
of births
Proportion in
sample (%)
Estimated
number
of births
Proportion in
sample (%)
Estimated
number
of births
Austria 77,800 NA (6.7) 5,213 (0.8) 622 (0) 0
Belgium 127,200 129 28.7 36,506 9.3 11,830 0 0
242c 23.2 29,510 7.2 9,158 0
Bulgaria 77,700 NA (4.2) 3,263 (1.2) 932 (0.8) 622
Croatia 43,800 234d 52.0 22,776 22.0 9,636 4.7 2,059
Cyprus 9,200 60 36.7 3,376 18.3 1,684 3.3 304
Czech Republic 119,600 120 5.0 5,980 0.8 957 0 0
Denmark 65,000 145 36.6 23,790 13.1 8515 0.7 455
Estonia 16,000 NA (10.0) 1,600 (2.0) 320 (0) 0
Faroe Islands 675 505e 62.6 423 30.2 204 5.3 36
Finland 59,500 NA (10.0) 5,950 (2.0) 1,190 (0) 0
France 829,300 126f 44.0 364,892 14.51 120,331 0.61 5,059
Germany 682,500 120 6.7 45,728 0.8 5,460 0 0
Greece 118,300 454d 78 92,274 57 67,431 14 16,562
Hungary 99,100 120 0.83 823 0 0 0 0
Ireland 74,000 120 10.8 7,992 2.5 1,850 0 0
Italy 576,700 891d + 115g (65.6) 378,315 (36.8) 212,226 (5.7) 32,872
Latvia 23,834 NA (10.0) 2,383 (2.0) 477 (0) 0
Lithuania 35,100 NA (10.0) 3,510 (2.0) 702 (0) 0
Luxembourg 5,600 55 32.7 1,831 18.2 1,019 0 0
Malta 4,100 NA (65.6) 2,690 (36.8) 1,509 (5.7) 234
Netherlands 184,600 NA (23.2) 42,827 (7.2) 13,291 (0) 0
Norway 60,500 119h 27.7 16,759 5.9 3,570 0 0
Poland 414,500 120 1.7 7047 0 0 0 0
Portugal 104,600 120 90.8 94,977 57.5 60,145 8.3 8,682
Romania 221,900 120 4.2 9,320 1.2 2,663 0.8 1,775
Slovakia 57,400 129 5.43 3,117 0.8 459 0 0
Slovenia 21,800 156 22.0 4,796 7.7 1,679 1.9 414
Spain 519,800 120 88.5 460,023 74.2 385,692 31.7 164,777
Sweden 109,300 100 10.0 10,930 2.0 2,186 0 0
Switzerland 76,700 120 5.0 3,835 2.1 1,611 0 0
United Kingdom 794,400 4134h 31.0 246,264 5.1 40,200 0 0
Total EU (27) 5,400,000 1,865,416 903,169 231,754
Exposures in EU countries without recent data are estimated from neighbouring countries (modelled results not based on observed distributions are given
in parenthesis).
a For countries without available exposure data (for number of samples, NA denotes not available), data from a neighbouring country have been applied to allow
EU-wide estimates, and frequencies are given in parenthesis. This applies to Austria (data from Germany were used), Bulgaria (Romania), Netherlands (Flanders [30]), and
Estonia, Finland, Latvia, and Lithuania (Sweden); b All data are from DEMOCOPHES, unless otherwise noted; c [30]; d [32]; e Pal Weihe, unpublished data; f [31]; g [33]; h
Jean Golding, pers.comm.
Bellanger et al. Environmental Health 2013, 12:3 Page 4 of 10
http://www.ehjournal.net/content/12/1/3from the Norwegian national birth cohort were used for
this country [34]. As DEMOCOPHES data from the United
Kingdom covered only a small rural sample, we relied
on data on blood-mercury in pregnant womenobtained from the ALSPAC birth cohort study in the
1990s [35]. Additional exposure data from Ukraine
[36] supported the notion that MeHg exposures in
Eastern Europe are low, with only small percentages
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too small to be used for detailed calculations. The
same applied to several other sources identified
(Miklavčič, unpublished data).
The estimated number of annual births in the EU that
exceed the 0.58 μg/g cut-off is about 1.8 million (Table 1,
Additional file 3). The EPA limit is exceeded in about
900,000 births, and the WHO limit in 200,000 births
within the EU. As each study is subject to sampling
uncertainty, log-normal distribution models showed
similar, though sometimes slightly higher, proportions
exceeding the 0.58 cut-off level (Table 2). The data from
Eastern European countries and from Croatia, the Faroe
Islands, Norway, and Switzerland suggest that, within
Europe, the great majority of births exceeding the
various limits occur in EU member states.
Table 2 presents the estimated IQ losses associated
with the MeHg exposures using the linear model, along
with the estimates of economic impacts. We used both
the observed data and the modelled distributions, and
only small differences were seen, thus supporting the
notion that the log-normal exposure distribution has an
appropriate fit. The greatest benefits accrue for the
largest countries with the highest proportions of subjects
with exposures above the cut-off level. The total benefit
from control of MeHg exposure was the highest for
Spain and the lowest for Hungary. On a per capita basis,
the calculated benefits are the greatest in the Faroe
Islands and the southern countries, Spain, Greece,
Portugal, Italy, and Croatia. The total annual benefits in
terms of IQ points within the EU were estimated to be
in excess of 600,000 per year for the linear DRC. With
an average benefit of €13,579 per IQ point, the total
economic benefits are estimated to exceed €9,000 million
per year. When adjustment for productivity is included,
the benefits are somewhat lower for several countries, and
the EU total is slightly less than €8,000 million per year
(Additional file 3).
For comparison, Table 3 shows the estimated IQ losses
and economic benefits using the log transformed DRF.
Due to the steeper curve shape at exposures close to the
cut-off point of 0.58 μg/g, the estimated benefits are
about 4-fold greater, at about 2.7 million IQ points per
year, which correspond to total benefits for the EU of
approximately €39,000 million or, after productivity
adjustment, €33,000 million.
Discussion
This study provides for the first time regional European
data on economic benefits of controlling MeHg exposure
in relation to prevention of developmental neurotoxicity.
It relies on data from a multi-country study of hair-Hg
concentrations with a high level of quality assurance and
with similar population sampling criteria. In addition,available data from other studies have been taken into
consideration to provide supplementary information,
thereby allowing EU-wide estimates to be calculated.
Given the low MeHg exposures in Eastern Europe and the
relatively small contributions from Croatia, the Faroe
Islands, Norway, and Switzerland, the results suggest that
benefits for all of Europe will not be substantially above
the benefits calculated for the EU.
Several assumptions and caveats must be acknowledged.
The hair-Hg concentration is an established biomarker of
human MeHg exposure and is generally considered
reliable [14]. We used available data from DEMOCOPHES
and other sources, with most studies including only about
120 subjects. The sampling size and strategy may have
underestimated the occurrence of uncommon high-level
exposures, which would weigh more in the calculation of
IQ benefits. Adjustment for this bias is obtained in the
modelled distributions, which tended to show slightly
greater benefits. Although these calculations rely on an
assumption of a log-normal distribution of the exposures,
the concurrence of the two sets of estimates support the
validity of this assumption.
In calculating the IQ benefits, we used a linear dose-
response function for the decrease in IQ at increased
prenatal MeHg exposures, and this curve shape is an
approximation of unknown validity. As has been
documented for lead [37], a logarithmic DRF may be
plausible, and a log curve shows a slightly better fit
[16]. As the results for the log curve (Table 3) are
about 4-fold higher than those obtained for the linear
curve, the benefits calculated in Table 2 must be considered
likely underestimates. In recent calculations using French
data using similar methods [8], the logarithmic curve shape
also resulted in substantially higher estimates.
The cut-off level assumed to be 0.58 μg/g hair may
also result in underestimated benefits. Recent data from
Poland [20], Japan [21] and the United States [18,19]
suggest that a lower threshold is likely. If the threshold
is indeed lower than we have assumed, the benefits of
controlling MeHg exposures will likely be greater,
although an additional effort may be required to achieve
such lower exposures. Further, given that the much
higher tolerable limit of 2.5 μg/g is likely exceeded by
200,000 births in the EU per year, clear benefits will accrue
already from controlling the very highest exposures.
The IQ benefits from controlling mercury pollution were
translated into economic impacts based on the calculated
current life-time income benefits from a higher IQ level.
These benefits are mainly based on studies carried out in
the United States [24,38], and it is possible that IQ-linked
differences in life-time incomes may not be the same in
Europe. Adjustment for differences in purchasing power
has been included to take this issue into partial account.
We used data from 2008 to secure complete data sources;
Table 2 Annual number of births with excess exposure, average hair-Hg concentration, IQ benefit from prevention of
excess exposure, and the value of the IQ benefits
Country Number of births above 0.58 μg/g Average
concentration
above 0.58 μg/g
Benefit in IQ points Value of 1
IQ point
(Euro)
Total benefit (million Euro)
Modelled Observed Modelled Observed Modelled Observed
Austria 3,812 5,213 0.917 597 817 16,044 9.6 13.1
Belgium 39,686 36,506 0.939 6,625 6,094 16,458 109.0 100.3
Bulgaria 3,186 3,263 1.455 1,296 1,328 7,529 9.8 10.0
Croatia 21,769 22,776 1.355 7,845 8,208 11,320 88.8 92.9
Cyprus 3,514 3,376 1.311 1,195 1,148 13,747 16.4 15.8
Czech Republic 5,143 5,980 0.847 639 742 10,797 6.9 8.0
Denmark 22,815 23,790 1.027 4,742 4,945 20,220 95.9 100.0
Estonia 1,840 1,600 0.846 228 198 10,339 2.4 2.0
Faroe Islands 406 423 1.323 140 146 20,220 2.8 2.9
Finland 6,843 5,950 0.846 846 736 17,288 14.6 12.7
France 405,528 364,892 0.989 70,186 69,397 17,363 1,218.6 1,204.9
Germany 33,443 45,728 0.917 5,241 7,166 15,292 80.1 109.6
Greece 94,403 92,274 1.563 50,131 49,000 13,201 661.8 646.9
Hungary 892 823 0.884 126 116 9,691 1.2 1.1
Ireland 7,104 7,992 0.946 1,209 1,360 17,927 21.7 24.4
Italy 378,315 (378,315) 1.045 81,801 (81,801) 17,062 1,395.7 (1,395.7)
Latvia 2,741 2,383 0.846 339 295 11,568 3.9 3.4
Lithuania 4,037 3,510 0.846 499 434 9,661 4.8 4.2
Luxembourg 1,870 1,831 1.212 550 538 17,062 9.4 9.2
Malta 2,690 (2,690) 1.045 582 (582) 11,111 6.5 6.5
Netherlands 45,227 42,827 0.909 6,919 6,552 15,857 109.7 103.9
Norway 16,759 16,759 0.866 2,237 2,229 20,051 44.8 44.7
Poland 6,218 7,047 0.751 494 560 9,979 4.9 5.6
Portugal 94,349 94,977 1.482 39,573 39,836 12,221 483.6 486.8
Romania 9,098 9,320 1.455 3,702 3,797 8,187 30.3 31.1
Slovakia 2,468 3,117 0.899 366 462 10,037 3.7 4.6
Slovenia 4,840 4,796 1.194 1,382 1,369 11,939 16.5 16.3
Spain 479,775 460,023 2.136 347,137 332,845 13,558 4,706.5 4,512.7
Sweden 12,570 10,930 0.846 1,555 1,352 17,167 26.7 23.2
Switzerland 6,520 3.835 0.902 976 574 18,346 17.9 10.5
United Kingdom 248,647 246,200 0.81 26,593 26,338 15,324 407.5 403.5
EU Total 1,926,652 1,865,365 654,551 639,804 9,458 9,256
Data are for European countries with information on methylmercury exposure distributions. For countries without detailed observed data available, the modelled
results are given in parenthesis. Sources of underlying data are as in Table 1.
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only slightly. An alternative approach might be to calculate
benefits from prevention of specific diseases, e.g. for men-
tal retardation or autism, associated with MeHg exposure.
However, the attributable risks associated with increases in
MeHg exposure are unknown, and such calculations are
therefore uncertain [10,39].
Some sources of imprecision in exposure estimates
must be emphasized. Thus, in several cases whenexposure information was not available for an EU mem-
ber state, data from a neighbouring country were used
as a proxy. Further, the results reported in
DEMOCOPHES and in published reports may not be
representative for each country. Although high fish
consumers may possibly have been oversampled, it is
more likely that the avoidance of known exposure hot-
spots resulted in lowered exposure estimates. In addition,
especially for small studies, an element of uncertainty
Table 3 Annual number of births with excess exposure, the average log hair-Hg concentration, and IQ benefit and
value from prevention of excess exposure (logarithmic dose-effect relationship)
Country Number of births
above 0.58 μg/g
Average log concentration
above 0.58 μg/g
Benefit in
IQ points
Value of 1 IQ
point (Euro)
Total benefit
(million Euro)
Austria 3,812 −0.157 3,199 16,044 51.3
Belgium 39,686 −0.128 35,790 16,458 589.0
Bulgaria 3,186 0.128 4,638 7,529 34.9
Croatia 21,769 0.142 32,350 11,320 366.2
Cyprus 3,514 0.109 4,972 13,747 68.3
Czech Republic 5,143 −0.216 3,658 10,797 39.5
Denmark 22,815 −0.060 23,932 20,220 483.9
Estonia 1,840 −0.214 1,317 10,339 13.6
Faroe Islands 406 0.139 600 20,220 12.1
Finland 6,843 −0.214 4,897 17,288 84.7
France 405,528 −0.053 368,742 17,363 6,402.5
Germany 33,443 −0.157 28,060 15,292 429.1
Greece 94,403 0.355 183,808 13,201 2,426.4
Hungary 892 −0.186 692 9,691 6.7
Ireland 7,104 −0.132 6,345 17,927 113.7
Italy 378,315 −0.036 416,490 17,062 7.106.2
Latvia 2,741 −0.214 1,962 11,568 22.7
Lithuania 4,037 −0.214 2,889 9,661 27.9
Luxembourg 1,870 0.053 2,419 17,062 41.3
Malta 2,690 −0.036 2,961 11,111 32.9
Netherlands 45,227 −0.155 38,144 15,857 604.8
Norway 16,759 −0.198 12,574 20,051 252.1
Poland 6,218 −0.312 3,131 9,979 31.2
Portugal 94,349 0.277 167,777 12,221 2,050.4
Romania 9,098 0.128 13,245 8,187 108.4
Slovakia 2,468 −0.173 1,986 10,037 19.9
Slovenia 4,840 0.034 6,061 11,939 72.4
Spain 479,775 0.561 1,148,026 13,558 15,564.9
Sweden 12,570 −0.214 8,996 17,167 154.4
Switzerland 6,520 −0.167 5,329 18,346 97.8
United Kingdom 248,647 −0.244 161,816 15,324 2,479.7
EU Total 1,884,563 2,645,953 39,061
Data from European countries, sources of underlying data are as in Table 1.
Bellanger et al. Environmental Health 2013, 12:3 Page 7 of 10
http://www.ehjournal.net/content/12/1/3exists with regard to the frequencies of the highest
exposures, although this problem was addressed by model-
ling a log-normal distribution of exposures. Temporal vari-
ation and time trends may also play a role, especially in
regard to older data. We have assumed stable diets, so that
any seasonal or other time trends as well as the time de-
pendence of MeHg sensitivity during brain development
would not matter for the calculation of impacts.
Our focus on the loss in life-time earnings is similar to
the avoidable costs previously calculated in relation to
lead exposure [24]. Other costs were ignored, such asdirect medical costs linked to treatment or interventions
for children with neurodevelopmental disorders. We also
neglected indirect costs, such as those related to special
education or additional years of schooling for children
as a consequence of these disorders, as well as intangible
costs. In addition, our study did not consider other
avoided direct health care costs in the longer term, such
as those potentially related to the treatment of cardio-
vascular or neurodegenerative effects of MeHg exposure,
which could be important for high fish consumers [2],
but would be difficult to estimate. Any compensation of the
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not taken into account. Overall, the estimates presented in
Table 2 are likely underestimates of the total benefits of
MeHg exposure abatement.
Clear differences are apparent between European coun-
tries. Seafood and freshwater fish constitute the main
source of exposure, but countries with high fish consump-
tion levels, such as Spain and Norway, clearly show great
differences in MeHg exposure that are undoubtedly related
to the choice of fish species consumed as well as the
contamination level. The high exposure levels observed in
Spain are in accordance with other studies [40,41]. The
elevated exposures in the Faroes are likely related to the
occasional consumption of pilot whale meat [23].
Calculations from the United States have resulted in
several greatly varying estimates, depending on the DRF
assumptions. One comparable estimate put the aggre-
gate economic benefit for each annual birth cohort in
the US at $8.7 billion (range: $0.7–$13.9 billion for year
2000) [10]. We recently calculated the annual benefit for
the US at about 264,000 IQ points, which would corres-
pond to benefits of approximately $5 billion [42]. The
EU benefits of over 600,000 IQ points are much higher.
However, in comparing the figures for the US and the
EU, note should be taken that annual number of births in
the EU (5.4 million) are 27% greater than the 4.2 million
births in the US per year. In addition, MeHg exposures in
parts of Europe are higher than in the US [4]. On a global
scale, benefit estimates can be extended on the basis of
GDP values adjusted for PPP and productivity, but the
validity of such calculations is limited by the lack of expos-
ure assessments [43]. However, the present study leaves
little doubt that global benefits substantially exceed $20
billion.
The present study did not aim at calculating annual
costs of investments in pollution abatement due to the
paucity of available data. Relevant investment costs
would consider mercury emissions controls in coal-fired
power plants, reduction of mercury usage in the chlorine
industry, measures taken in dentistry, plus expenses for
recycling and treatment of mercury releases. Some
information is available and suggests that one-time
expenses may be quickly balanced by the cumulated annual
benefits from exposure abatement [9]. However, mercury
emissions control needs to be carried out on a global level
due to the regional and hemispherical dispersion of
mercury releases [43]. These costs would likely have
additional socioeconomic yields from better control of
mercury emissions, e.g. job creation and modernization
of capital equipment.
The control of inorganic mercury emissions will only
result in diminished MeHg exposure in the long term,
and the benefits will therefore be delayed. As MeHg
exposure mainly originates from seafood andfreshwater fish, public health advice on dietary choices is
an important element of the intervention [6,44]. Due to
the essential nutrients present in seafood [3], a reduction
in MeHg exposure should not be sought through a de-
crease or replacement of fish in the diet. A prudent advice
would be to maintain fish consumption and minimise the
MeHg exposure by consumption of fish known to have
lower MeHg concentrations, e.g., smaller species, younger
fish, and catches from less polluted waters. Such advice
should be directed toward women during pregnancy as the
most cost-effective preventive action. Restricted consump-
tion of large, piscivorous fish species may also benefit
overfished populations of pelagic fish, such as tuna [45].
The successful completion of the DEMOCOPHES
project and the complements from other exposure stud-
ies in Europe illustrate the feasibility and usefulness of
biological monitoring approaches, in particular when
relying on hair samples that may be easily obtained,
stored and transported. While such studies have become a
routine function in the United States through the National
Health And Nutrition Examination Survey [4], and the
biomonitoring reports from the Centers for Disease
Control and Prevention have become key resources for
research on human exposures to environmental chemicals,
Europe has lagged behind. Following international policy
decisions to decrease global mercury pollution, such human
biomonitoring studies will be crucial to monitor the effects
of the interventions.
Conclusions
Annual benefits of removing Hg exposure can be
estimated to be approximately €9 billion in Europe.
While our results support enhanced public policies for
the prevention of MeHg exposure, the economic
estimates are highly influenced by uncertainties
regarding the dose-response relationship. Thus, a loga-
rithmic response curve results in 4-fold higher benefit
estimates. In addition, benefits might be underestimated
because costs linked to all aspects of neurotoxicity and
long-term disease risks have not been considered. These
European data and the calculated economic benefits
support the need for interventions to minimize expos-
ure to this hazardous pollutant.Additional files
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